Article Figures & Data
Figures
- Fig 1.
An unruptured terminal left internal carotid aneurysm is seen before (A) and immediately after (B) coil embolization. Coil loops protrude slightly into the parent artery (arrow, B). Thirty minutes after coil embolization, thrombus has formed within the arteries adjacent to the coils (C) and embolized to distal branches (arrows, D).
Tables
Variable Antiplatelet Drugs: Before and After Antiplatelet Drugs: After Only No Antiplatelet Drugs P Statistical Test Women 188/258 (72.9) 69/86 (80.2) 20/25 (80.0) .3285 X2 (2 × 3) Men 70/258 (27.1) 17/86 (19.8) 5/25 (20.0) .3285 X2 (2 × 3) Age, y 55.68 53.45 57.80 .1922 One-way ANOVA Diameter of first framing coil, mm 6.3 7.0 7.3 .1834 One-way ANOVA Prolapsed coil 30/258 (11.6) 8/86 (9.3) 3/25 (12.0) .7840 X2 (2 × 3) Coated coils 64/258 (24.8) 10/86 (11.6) 1/25 (4.0) .0014* X2 (2 × 3) Balloon 32/258 (12.4) 8/86 (9.3) 1/25 (4.0) .3098 X2 (2 × 3) Stent (total) 52/258 (20.2) 6/86 (7.0) 0/25 (0.0) .0001* X2 (2 × 3) Note:—Raw values are reported in each cell. Percentage of the population is in parentheses. ANOVA indicates analysis of variance.
* denotes statistically significant P value.
Treatment Category Symptomatic Thromboembolic Complication Postprocedure TIA (≤24 h) Postprocedure Ischemic Stroke (≤24 h) TIA Between 1 and 60 Days Ischemic Stroke Between 1 and 60 Days Antiplatelet therapy (before and after) 1 0 3* 1† Antiplatelet therapy (after only) 0 0 2‡ 0 No drugs 2 1§ 0 2§ Note:—TIA indicates transient ischemic attack.
* One each at 3, 39, and 60 days postprocedure.
† At 50 days postprocedure.
‡ One each at 34 and 38 days postprocedure.
§ One patient suffered 2 ischemic strokes, 1 within 24 hours and 1 at 6 days postprocedure.
Treatment Category Symptomatic Thromboembolic Complication No, n (Row %) Yes, n (Row %) Total N Antiplatelet therapy (before and after) 253 (98.1) 5 (1.9) 258 Antiplatelet therapy (after only) 84 (97.7) 2 (2.3) 86 No drug 21 (84.0) 4 (16.0) 25 Total N 358 11 369 Note:—X2 indicates likelihood ratio; P =.0133. The percentage of patients in the “before and after” group (1.9%) who had thromboembolic complications is very comparable with the percentage of patients in the “after only” group (2.3%).
Binary Treatment Category Symptomatic Thromboembolic Complication No, n (Row %) Yes, n (Row %) Total N Antiplatelet therapy 337 (98.0) 7 (2.0) 344 No drug 21 (84.0) 4 (16.0) 25 Total N 358 11 369 Note:—Fisher exact test indicates 2-tail P = .0039. An alternative hypothesis is that thromboembolic complication rate is different across treatment categories.
Binary Treatment Category Hemorrhagic Complication No, n (Row %) Yes, n (Row %) Total N Antiplatelet therapy 332 (96.8) 11 (3.2) 343 No drug 24 (100.0) 0 (0.0) 24 Total N 356 11 367 Note:—Fisher exact test indicates 2-tail P = 1.000. An alternative hypothesis is that hemorrhagic complication rate is different across treatment categories.
In this issue
Jump to section
Related Articles
Cited By...
- The Prophylactic Use of Tirofiban versus Oral Antiplatelet Medications in Stent-Assisted Coiling of Intracranial Aneurysms: A Meta-analysis
- Use of pCONUS HPC for the treatment of unruptured wide-necked bifurcation aneurysms: early clinical experience using single antiplatelet therapy
- Active management of the target P2Y12 reaction unit range in patients undergoing stent-assisted coil embolization for unruptured cerebral aneurysms
- Antiplatelet therapy for prevention of thromboembolic complications in coiling-only procedures for unruptured brain aneurysms
- Comparison of Prasugrel and Clopidogrel Used as Antiplatelet Medication for Endovascular Treatment of Unruptured Intracranial Aneurysms: A Meta-Analysis
- The Neuroform Atlas stent to assist coil embolization of intracranial aneurysms: a multicentre experience
- Efficacy of a two-test protocol for achieving a therapeutic response to clopidogrel prior to elective endovascular intracranial aneurysm treatment and an 'induced postoperative hyper-response
- Prophylactic Antiplatelet Medication in Endovascular Treatment of Intracranial Aneurysms: Low-Dose Prasugrel versus Clopidogrel
- Intraprocedural abciximab bolus versus pretreatment oral dual antiplatelet medication for endovascular stenting of unruptured intracranial aneurysms
- Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms
- Association between Postprocedural Infarction and Antiplatelet Drug Resistance after Coiling for Unruptured Intracranial Aneurysms
- Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy
- Silent embolism after stent-assisted coiling of cerebral aneurysms: diffusion-weighted MRI study of 75 cases
- Off-Label Use of Drugs and Devices in the Neuroendovascular Suite
- Prasugrel is effective and safe for neurointerventional procedures
- Point of care platelet function testing in routine neurointerventional care is unjustified
- Canadian Experience with the Pipeline Embolization Device for Repair of Unruptured Intracranial Aneurysms
- Long-term effects of antiplatelet drugs on aneurysm occlusion after endovascular treatment
- Small unruptured partially thrombosed aneurysms and stroke: report of three cases and review of the literature
- Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications
- Safety of intravenous heparin administration after endovascular treatment for ruptured intracranial aneurysms
- Abciximab Is a Safe Rescue Therapy in Thromboembolic Events Complicating Cerebral Aneurysm Coil Embolization: Single Center Experience in 42 Cases and Review of the Literature